<DOC>
	<DOCNO>NCT01721993</DOCNO>
	<brief_summary>THAR2011-1 Phase I , single dose , open-label dose-escalation study determine safety , absolute bioavailability , dose proportionality , pharmacokinetics T121 healthy postmenopausal woman . The study expect identify safe dose test subsequent multiple dose study compare safety , PK pharmacodynamics ( PD ) T121 currently market IV zoledronic acid ( Zometa ) .</brief_summary>
	<brief_title>Open Label Dose Escalation Phase I Study Investigate Safety Pharmacokinetics T121E01F T121E02F Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Healthy , postmenopausal woman age 35 70 year , inclusive . Postmenopausal females ( base medical history ) define 12 continuous month spontaneous amenorrhea bilateral oophorectomy . Women 60 year age old consider postmenopausal . Women 3559 must serum folliclestimulating hormone ( FSH ) result consistent postmenopausal state . Body Mass Index ( BMI ) 17.5 32 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Signed informed consent • Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . History severe allergic reaction know allergy ZA . Evidence history gastrointestinal disease , irritable bowel syndrome , Crohn 's Disease , chronic gastritis , peptic ulcer disease , H. pylorus infection , gastrointestinal condition possibly affect drug absorption . History gastric surgery , include RouxenY gastric bypass surgery antrectomy vagotomy , gastrectomy . Evidence history clinically significant cardiovascular ( CV ) disease condition , include : Any history major CV event ( myocardial infarction , unstable angina , cerebrovascular accident , transient ischemic attack ) ; Any history significant cardiac arrhythmia , implant artificial pacemaker ; Blood pressure great 150/90 heart rate great 100 screening ; Clinically significant abnormality 12lead ECG , include QTc &gt; 450 msec ( heartrate correct use Fridericia formula ) Screening . History autoimmune disease ( e.g. , systemic lupus erythematosus [ SLE ] , scleroderma , psoriasis , vitiligo , primary biliary cirrhosis , etc. ) . Active/ongoing endocrine disorder ( e.g. , type 1 diabetes , adrenal insufficiency , hypoparathyroidism , etc . ) except well control thyroid disease type II diabetes HgbA1C &lt; 8 permit . Mucolipidosis type IV . Any clinically significant hematological condition ( e.g. , pernicious anemia ) . Evidence history severe acute chronic medical ( include renal , pulmonary , hepatic , neurologic , psychiatric , etc . ) disease condition laboratory abnormality may increase risk associate study participation investigational product administration , may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . History evidence Paget 's disease bone ( osteitis deformans ) relate disorder . A positive urine drug screen . A positive pregnancy test . History difficulty swallow large pills/tablets . Active dental oral disease would increase risk bisphosphonate use and/or require dental care . Prohibited substance use , include : Any documented history drug alcohol abuse within previous 10 year ; Chronic consumption past 12 month 2 standard unit per day alcohol ( standard unit equal 12 ounce beer , 1 ½ ounce 80proof alcohol 6 ounce wine ) ; Subject report tobacco nicotine use within 30 day admission . Prohibited medication use , include : Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication , whichever longer ; Use nonprescription drug dietary and/or vitamin supplement within 7 day prior first dose study medication . Use acetaminophen acceptable management acute ( e.g. , pain ) condition , long daily dose &lt; 2000 mg duration exceed 3 consecutive day . The need new prescription nonprescription drug ( ) supplement study discuss Medical Monitor ; Prescription herbal supplement within 14 day prior first dose study medication ; History chronic proton pump inhibitor ( PPI ) use Proton pump inhibitor , H2 blocker , hormone replacement therapy , aminoglycosides , loop diuretic nephrotoxic drug within 30 day prior first dose study medication ; Bisphosphonate use within 90 day prior first dose study medication ; Use nonsteroidal antiinflammatory drug ( NSAID ) within 7 day prior 7 day administration study medication ; Use acid reducer medication include antacid component , nonprescription prescription , within 7 day prior 1 day administration study medication ; Use loop diuretic . A positive serology Hepatitis B , Hepatitis C , HIV , H. pylorus . An indeterminate H. pylori result must confirm H. Pylori breath test . A positive result exclusionary . Any invasive dental oral procedure complete within 30 day prior first dose study medication anticipate study within 30 day completion study . Clinically significant abnormal laboratory test value , determine Investigator , follow : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , creatinine 1.5 time upper limit normal ( ULN ) ; platelet low limit normal ; hemoglobin 10 % low level normal ; normal range value serum sodium , serum calcium , serum potassium serum magnesium ; Glomerular filtration rate ( eGFR ) &lt; 60 mL/ minute calculate modified Modification Diet Renal Disease ( MDRD ) formula .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>oral zoledronic acid</keyword>
</DOC>